Effect of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia in children

Objective:To observe the clinical effects of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia(MPP) in children,and evaluate its effect on cellular immune function.Methods:Forty-four children with lobar MPP were randomly divided into group A and group B,and 30 healthy children were set as control group.Group B were treated with azithromycin(10 mg·kg^-1·d^-1 each time) for 3 courses of treatmemt,and the group A were treated with azithromycin combined with pidotimod(0.4 g/d) for 2 months.The levels of T lymphocyte subsets in three group before treatment and after 2 months of treatment were detected using flow cytometry,and the clinical effect between group A and B was compared.Results:Before treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in lobar MPP group significantly decreased,and the level of CD8⁺ increased compared with the control group(P<0.01).After treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in group A significantly increased compared with before treatment(P<0.01),and the difference of which in group B between before and after treatment was not statistically significant(P>0.05).After treatment,the differences of the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ between group A and group B were statistically significant(P<0.01),and the difference of the level of serum CD8⁺ in two groups between before and after treatment was not statistically significant(P>0.05).From the beginning of treatment to follow for 6 months,the clinical curative effect in group A was better than that in group B(P<0.01).Conclusions:Cellular immune function disorder exists in lobar MPP,pidotimod can regulate the immune balance,strengthen immunity,and improve the clinical curative effect in children with lobar MPP.